Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Agalsidase benefits renal histology in young patients with Fabry disease.

Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E.

J Am Soc Nephrol. 2013 Jan;24(1):137-48. doi: 10.1681/ASN.2012030316.

2.

Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.

Skrunes R, Svarstad E, Kampevold Larsen K, Leh S, Tøndel C.

Nephrol Dial Transplant. 2017 May 1;32(5):807-813. doi: 10.1093/ndt/gfw094.

PMID:
27190352
3.

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.

Lubanda JC, Anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska A.

Genet Med. 2009 Apr;11(4):256-64. doi: 10.1097/GIM.0b013e3181981d82.

PMID:
19265719
4.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
5.

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.

Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, Steiner RD, Beck M, Barshop BA, Rhead W, West M, Martin R, Amato D, Nair N, Huertas P.

Genet Med. 2013 Dec;15(12):983-9. doi: 10.1038/gim.2013.56. Epub 2013 May 16.

PMID:
23680766
6.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
7.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.

Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4. Review.

PMID:
27454104
8.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N.

J Am Soc Nephrol. 2007 May;18(5):1547-57. Epub 2007 Apr 4.

9.

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.

Lenders M, Canaan-Kühl S, Krämer J, Duning T, Reiermann S, Sommer C, Stypmann J, Blaschke D, Üçeyler N, Hense HW, Brand SM, Wanner C, Weidemann F, Brand E.

J Am Soc Nephrol. 2016 Mar;27(3):952-62. doi: 10.1681/ASN.2015030337. Epub 2015 Jul 16.

10.

Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.

Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, Guerrero González H, Sommer C, Üçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E.

J Am Soc Nephrol. 2014 Apr;25(4):837-49. doi: 10.1681/ASN.2013060585. Epub 2014 Feb 20.

11.

Renal histology before and after effective enzyme replacement therapy in a patient with classical Fabry's disease.

Hirashio S, Taguchi T, Naito T, Maki K, Ogata S, Taniyama K, Taniguchi Y, Yorioka N.

Clin Nephrol. 2009 May;71(5):550-6.

PMID:
19473616
12.

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.

Goker-Alpan O, Longo N, McDonald M, Shankar SP, Schiffmann R, Chang P, Shen Y, Pano A.

Drug Des Devel Ther. 2016 May 25;10:1771-81. doi: 10.2147/DDDT.S102761. eCollection 2016.

13.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE.

Orphanet J Rare Dis. 2011 Oct 31;6:69. doi: 10.1186/1750-1172-6-69.

14.

Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.

Lin HY, Huang YH, Liao HC, Liu HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin SP, Niu DM.

J Chin Med Assoc. 2014 Apr;77(4):190-7. doi: 10.1016/j.jcma.2013.11.006. Epub 2013 Dec 30.

15.

Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.

Kanai T, Ito T, Odaka J, Saito T, Aoyagi J, Betsui H, Yamagata T.

Eur J Pediatr. 2016 Mar;175(3):427-31. doi: 10.1007/s00431-015-2646-x. Epub 2015 Oct 10.

PMID:
26454753
16.

[Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].

Thomaidis T, Relle M, Reinke J, Beck M, Schwarting A.

Med Klin (Munich). 2009 Sep 15;104(9):699-703. doi: 10.1007/s00063-009-1152-1. Epub 2009 Sep 23. Review. German.

PMID:
19779674
17.
18.

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP; International Fabry Disease Study Group.

Am J Hum Genet. 2004 Jul;75(1):65-74. Epub 2004 May 20.

19.

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.

Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, Kobayashi Y, Abiko H, Satou M, Nakahata T, Warnock DG, Sakuraba H, Shibasaki F.

PLoS One. 2015 Jun 17;10(6):e0128351. doi: 10.1371/journal.pone.0128351. eCollection 2015.

20.

Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.

Skrunes R, Tøndel C, Leh S, Larsen KK, Houge G, Davidsen ES, Hollak C, van Kuilenburg ABP, Vaz FM, Svarstad E.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1470-1479. doi: 10.2215/CJN.01820217. Epub 2017 Jun 16.

PMID:
28625968

Supplemental Content

Support Center